IL2 and metastatic melanoma: In a study done by Rosenberg and his collaborators, 409 patients with either metastatic melanoma or renal carcinoma, were treated with a high-dose of IL-2 (720,000 lU/kg), a complete response was observed in 8.1% patients, and a partial response in 9% patients.